Alexion Pharmaceutic

ALXN
Delayed Nasdaq - 01/24 10:15:00 pm
105.27USD
-3.02%
Prev.108.5500
Open109.0500
High109.1500
Low104.6350
Volume1 760 097
Financials
Sales 2019 4 924 M
EBIT 2019 2 796 M
Net income 2019 1 972 M
Finance 2019 164 M
Yield 2019 -
P/E ratio 2019 12,0x
P/E ratio 2020 11,2x
EV / Sales2019 4,70x
EV / Sales2020 3,78x
Capitalization 23 295 M
Company
Alexion Pharmaceuticals specializes in the research and development of therapeutic products used in treating hematological and cardiovascular diseases, auto-immune diseases, and cancers.
At the end of 2018, the group had a portfolio of 6 products in clinical development.
Net sales are distributed...
Sector :
Biopharmaceuticals
Calendar :
2020-01-30 Earnings Release
Trading Rating :
Investor Rating :
Latest news
01/24UPDATED TIME : Alexion Fourth Quarter and Full Year 2019 Results Conference Call at 7:30am ET on Thursday, January 30, 2020
BU
01/20ALEXION PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2019 Results on Thursday, January 30, 2020
AQ
01/17ALEXION PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2019 Results on Thursday, January 30, 2020
BU
01/15ALEXION PHARMACEUTICALS : Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS in ALS
AQ
01/14ALEXION PHARMACEUTICALS : Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS® (ravulizumab) in ALS
BU
01/13ALEXION PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/06ALEXION PHARMACEUTICALS : to Present at the 38th Annual J.P Morgan Healthcare Conference
BU
2019ALEXION PHARMACEUTICALS : Achillion Shareholders Approve Agreement to be Acquired by Alexion
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishNeutralBearish
Resistance109123118
Spread/Res.-3,6%-15%-11%
Spread/Supp.1,8%11%7,7%
Support10394,897,8